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Abstract
Background: Studies of human polyomavirus (HPyV) infection and lung cancer are limited and those regarding the
association of human papillomavirus (HPV) infection and lung cancer have produced inconsistent results.
Methods: We conducted a nested case–control study to assess the association between incident lung cancer of
various histologies and evidence of prior infection with HPyVs and HPVs. We selected serum from 183 cases and
217 frequency matched controls from the Yunnan Tin Miner’s Cohort study, which was designed to identify
biomarkers for early detection of lung cancer. Using multiplex liquid bead microarray (LBMA) antibody assays, we
tested for antibodies to the VP1 structural protein and small T antigen (ST-Ag) of Merkel cell, KI, and WU HPyVs. We
also tested for antibodies against HPV L1 structural proteins (high-risk types 16, 18, 31, 33, 52, and 58 and low-risk
types 6 and 11) and E6 and E7 oncoproteins (high risk types 16 and 18). Measures of antibody reactivity were log
transformed and analyzed using logistic regression.
Results: We found no association between KIV, WUV, and MCV antibody levels and incident lung cancer
(P-corrected for multiple comparisons >0.10 for all trend tests). We also found no association with HPV-16, 18, 31,
33, 52, and 58 seropositivity (P-corrected for multiple comparisons >0.05 for all).
Conclusions: Future studies of infectious etiologies of lung cancer should look beyond HPyVs and HPVs as
candidate infectious agents.
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Background
In China, lung cancer is the most commonly diagnosed
cancer in males, the second most common in females,
and the leading cause of cancer related death for both
sexes by a substantial margin [1]. The burden of lung
cancer in China is also rising, with disability-adjusted life
years per 100,000 increasing by more than 50 % between
1990 (552, 95 % confidence interval (CI): 458–782) and
2010 (843, 95 % CI: 590–990) [2]. Smoking, air pollution
(industrial emissions, cooking exhaust, second hand
smoke, and residential radon), and genetics are estab-
lished lung cancer risk factors that explain the majority,
but not all, of this burden of disease [3, 4]. However,
seven viruses are known to be causally associated with
human cancers [5], with their carcinogenic potential
often realized only in the presence of environmental mu-
tagens and other cofactors [6]. Due to the lung’s propen-
sity for infection, it is possible that some lung cancers
may have an infectious etiology.
The 2008 discovery of Merkel cell carcinoma’s associ-
ation with Merkel cell polyomavirus (MCV) provided
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the first evidence that human polyomaviruses (HPyVs)
may have carcinogenic potential in humans [7]. Since
MCV and other polyomaviruses such as KI (KIV) and
WU (WUV), can infect the lower respiratory tract [8–10],
their association with lung cancer has been previously
examined, but results have been inconclusive. Small MCV
studies have reported prevalence estimates of up to nearly
40 % for MCV DNA in lung tumors [11–14]. Less
consistency has been observed in studies of the associ-
ation of KIV and WUV with lung cancer. A small
European study reported that KIV DNA was found in
45 % (9/20) of lung tumors but only 5 % (1/20) of control
tissue [15]. However, these results were not confirmed by
additional studies which examined KIV and or WUV in
lung tumors [16–18]. Despite prior infection with human
polyomaviruses being nearly ubiquitous [19], prior studies
report that high levels of MCV antibodies were associated
with Merkel cell carcinoma [20]. However, in the only
other seroepidemiologic study, antibodies to MCV, KIV
and WUV were not associated with lung cancer in a US
population [21]. Nevertheless, given the influence of host
genetics on susceptibility to cancer, these associations may
differ in different populations.
The human papillomavirus (HPV) family has undisputed
carcinogenic potential, with HPV infection playing a causal
role in nearly all cervical cancers, a large proportion of
other anogenital cancers, and more than a quarter of oro-
pharyngeal cancers [22, 23]. In addition, HPV infections are
involved in the development of respiratory papillomas [24],
which occasionally exhibit malignant transformation [25].
Based on this evidence, there have been numerous studies
of the association between HPV infection and lung cancer.
In 2009, a meta-analysis and a systematic review independ-
ently concluded that the evidence for an association
remained inconclusive, but stronger associations were ob-
served in East Asia [26, 27]. More recently, a 2015 meta-
analysis concluded that HPV infection is associated with in-
creased risk for lung cancer [28]. However, only nine stud-
ies were included in the analysis, with all of the studies
having tested lung tissue for current evidence of infection
as opposed to longitudinally collected sera that could be
used to assess prior infection. In addition, the degree of het-
erogeneity reported was not inconsequential and the meta-
analysis used only crude data, which was unadjusted for po-
tential confounders such as age and smoking status [29]. Fi-
nally, as the authors noted, there were some indications of
publication bias. Therefore, HPV’s association with lung
cancer remains an open question.
Methods
Study population
Between 1992 and 1998, 9,295 eligible Yunnan Tin Cor-
poration (YTC) employees were enrolled in a cohort
study of early markers of lung cancer in Yunnan, China
[30]. Participants were current or retired YTC workers,
at least 40 years of age, with a history of at least 10 years
underground and/or smelting experience, and no previ-
ous malignancies (except non-melanoma skin cancer).
Data and specimen collection
Participants completed an interviewer-administered
questionnaire regarding demographics, lung cancer
symptoms, eating habits, and medical, smoking and oc-
cupational history. They also received at least one yearly
screening exam consisting of sputum cytology, chest x-
rays, and a physical exam provided by the YTC General
Worker’s Hospital. All positive, and 2 % of negative, cy-
tology slides were re-read for diagnosis and adequacy of
preparation by YTC and a Johns Hopkins University
pathologist. Two radiologists read each chest x-ray, with
differences resolved by a third reader. In addition, yearly
sputum specimens and a one-time sample of urine,
10 mL of whole blood, and toenail clippings were col-
lected and preserved for future studies. Plasma was sepa-
rated from whole blood and stored at −70 °C. Follow-up
activities ceased on December 31, 2001.
Participants provided signed informed consent and the
institutional review boards (IRBs) of the National Cancer
Institute (NCI) and the YTC approved the original co-
hort study. The IRBs of the University of Washington,
the Fred Hutchinson Cancer Research Center, the Can-
cer Institute of the Chinese Academy of Medical Sci-
ences, and the NCI approved this analysis.
Case definition
Cases (n = 183) are defined as individuals with incident
lung cancer of any histology (small cell carcinoma, squa-
mous cell carcinoma, adenocarcinoma, and other). Inci-
dent lung cancer was determined in one of four ways: 1)
detection during annual screenings utilizing chest x-rays
and sputum cytology, followed-up by confirmatory diag-
nosis at the YTC General Worker’s Hospital, 2) presen-
tation to and diagnosis at the YTC General Worker’s
Hospital among those with symptoms, 3) searching the
YTC cancer registry system which contains data from
local hospitals, or 4) searching hospital based vital re-
cords for deceased cohort members and identifying the
cause of death. Controls (n = 217) were frequency
matched on age and the number of freeze-thaw cycles.
Since only two of the lung cancer cases occurred in
women, this study was limited to men.
Exposure assessment
We used a Bio-Plex 200 instrument (Bio-rad Laborator-
ies) to perform multiplex liquid bead microarray
(LBMA) antibody assays following standard procedures
[20, 31, 32]. We obtained and analyzed the median fluor-
escent intensity (MFI), a surrogate for antibody titer. We
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tested sera for antibodies against the VP1 structural pro-
tein and small T antigen (ST-Ag) oncoprotein of Merkel
cell, KI, and WU HPyVs. In addition, we tested for anti-
bodies against HPV L1 structural proteins (high-risk
types 16, 18, 31, 33, 52, and 58 and low-risk types 6 and
11) and E6 and E7 oncoproteins (high risk types 16 and
18 only). Glutathione S-transferase (GST) fusion pro-
teins and BK virus antigens served as negative and posi-
tive controls, respectively. All fusion proteins had an
eleven amino acid epitope “Tag” added to the C-
terminus to assess expression levels [20]. Between
89.3 % and 95 % of sera were seropositive for BK VP1,
depending on whether we used a threshold of 400 or
200 MFI, respectively. Sera were incubated at a final
concentration of 1:100.
Statistical methods
Since HPyV infection was expected to be common, we
compared the range of MFI between cases and controls
rather than dichotomizing specimens as seropositive or
seronegative. We assessed the association between HPyV
infection and lung cancer using MFI quartiles as the in-
dependent variable in logistic regression analyses. In
contrast, we dichotomized HPV MFI in order to in-
crease comparability of our HPV analysis with prior
LBMA based studies. We defined HPV seropositivity as
>400 MFI (>5.99 log transformed MFI (lnMFI)) [31, 33,
34] in our primary analysis and >200 MFI (>5.30 lnMFI)
[34, 35] in a sensitivity analysis. We also assessed the as-
sociation between each viral antibody and incident lung
cancer using logistic regression trend tests with continu-
ous lnMFI as the independent variable. MFI were log
transformed and all logistic regression analyses were ad-
justed for matching variables.
Since a total of 18 antibodies were assessed for an as-
sociation with incident lung cancer, we created exposure
categories to account for multiple comparisons. We cre-
ated three categories of HPyV exposure: MCV (VP1 and
ST-Ag), KIV (VP1 and ST-Ag), and WUV (VP1 and ST-
Ag). Similarly, four categories of HPV exposure were
created: low-risk HPV (6, 11 L1), HPV-16 (E6, E7, and
L1), HPV-18 (E6, E7, and L1), and other high-risk HPV
(31, 33, 52, 58 L1). We corrected our P-values for mul-
tiple comparisons by using permutation tests with
10,000 permutations to establish a null distribution of
the most significant exposure across the multiple expo-
sures in each exposure category [36]. The proportion of
the time that the empirical test statistic was less than or
equal to the test statistic calculated using permuted
datasets was defined as the corrected P-value.
We assessed effect modification by smoking history
(linear pack-years), radon exposure (Working Level
Month (WLM)), and arsenic exposure (Index of Arsenic
Exposure Months (IAEM)) using likelihood ratio tests. If
radon, and arsenic exposure were not effect modifiers,
they were considered potential confounders, along with
smoking history and a family history of lung cancer (yes,
no). If inclusion of a candidate confounder in the regres-
sion models changed the odds ratio (OR) of interest by
< 10 %, that candidate was not included in the final
model.
In exploratory analyses, boxplots were used to assess
the association of antigen-specific MFI with individual
histologic types.
All analyses used two-sided statistical tests and were
performed with Stata/IC 13.1 (StataCorp LP, College
Station, TX).
Results
The age distribution was similar between cases and con-
trols, but the controls were better educated (P = 0.04)
(Table 1). Cases were more likely to have ever smoked
tobacco (96.7 % vs. 90.8 %, P = 0.02), but had similar
overall levels of tobacco, arsenic, and radon exposure.
Nearly two-fifths of the cases had squamous cell carcin-
oma (39.3 %), 16.9 % had adenocarcinoma, 13.7 % had
small cell carcinoma, 10.4 % had a mixed histology, and
19.7 % had other histologies or the histology was not
obtained.
The distribution of antigen specific antibodies was
similar among lung cancer cases and controls (Table 2).
The maximum difference in the mean lnMFI between
cases and controls was 0.3 for HPV 16 E7 and HPV
11 L1 antibodies.
In multivariate analyses there was little evidence for
confounding so the models were adjusted only for
matching variables in the main analysis. The results of
the regression analysis comparing the highest to the low-
est quartile of MCV antibodies with respect to incident
lung cancer found no appreciable association for either
VP1 (aOR = 0.90, 95 % CI: 0.37-2.17) or ST-Ag (aOR =
0.85, 95 % CI: 0.48-1.48) (Table 3). Compared to men
with the lowest levels of KIV antibodies, those with the
highest quartile of VP1 (aOR = 1.44, 95 % CI: 0.82-2.52)
and ST-Ag (aOR = 1.13, 95 % CI: 0.65-1.98) did not face
a significantly increased risk of lung cancer. Those with
the highest quartile of WUV VP1 (aOR = 1.47, 95 %
CI: 0.84-2.58) and WUV ST-Ag (aOR = 1.02, 95 % CI:
0.58-1.78) antibodies also showed no evidence of in-
creased risk. Linear trend tests of these associations
confirmed the lack of association (P > 0.10 for all
HPyV antibodies). A sensitivity analysis that included
adjustment for education and ever smoking, both of
which were associated with case status, did not differ
substantially from the main analysis (<10 % change in
the odds ratio) (Additional file 1: Table S1).
HPV 16 L1 (aOR = 1.17, 95 % CI: 0.43-3.21) seroposi-
tivity was not associated with increased lung cancer risk
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Table 1 Characteristics of selected lung cancer cases and frequency matched controls: Yunnan, China 1992-1998
Characteristic Cases (n = 183) Controls (n = 217) P
n % n %
Age 0.914
40–49 3 (1.6) 4 (1.8)
50–59 58 (31.7) 71 (32.7)
60–69 104 (56.8) 125 (57.6)
70–79 18 (9.8) 17 (7.8)
Education levela 0.043
None 82 (44.8) 87 (40.1)
K–5 89 (48.6) 98 (45.2)
6–8 9 (4.9) 15 (6.9)
9–12 2 (1.1) 5 (2.3)
College 1 (0.5) 12 (5.5)
Body Mass Index (BMI) (kg/m2) 0.230
Underweight (<18.5) 18 (9.8) 36 (16.6)
Normal (18.5–24.99) 138 (75.4) 150 (69.1)
Overweight (25–29.99) 24 (13.1) 29 (13.4)
Obese (≥30) 3 (1.6) 2 (0.9)
Ever smoked tobaccob 177 (96.7) 197 (90.8) 0.016
Pack-years, median (IQRc) 36 (24–54) 32 (19–49) 0.132
Arsenicd, median (IQRc) 10745 (6695–15347) 9420 (4888–16802) 0.057
Radone, median (IQRc) 498 (277–783) 417 (171–681) 0.132
Family history of lung cancerf 3 (1.6) 6 (2.8) 0.449
Any prior lung diseaseg 88 (48.1) 98 (45.2) 0.559
Asthma or hay fever 25 (13.7) 24 (11.1) 0.429
Tuberculosis (self-report) 8 (4.4) 14 (6.5) 0.363
Chronic bronchitis 72 (39.3) 78 (35.9) 0.484
Silicosis 20 (10.9) 18 (8.3) 0.371
Lung cancer histology NA
Squamous cell carcinoma 72 (39.3) 0 (−)
Adenocarcinoma 31 (16.9) 0 (−)
Small cell carcinoma 25 (13.7) 0 (−)
Mixed 19 (10.4) 0 (−)
Other 2 (1.1) 0 (−)
Not obtained 34 (18.6) 0 (−)
Lung cancer site NA
Main bronchus 15 (8.2) 0 (−)
Upper lobe bronchus or lung 76 (41.5) 0 (−)
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(Table 4). HPV 18 L1 seropositivity also showed no evi-
dence of increased risk (aOR = 0.29, 95 % CI: 0.03-2.66).
Seropositivity to other high-risk HPV types and low-risk
HPV types also showed no relationship with lung cancer
incidence (adjusted P > 0.05 for all). The aOR for linear
trend tests of HPV lnMFI in association with incident
lung cancer ranged from 1.00 (95 % CI: 0.90-1.11) for
HPV 52 L1 to 1.17 (95 % CI: 0.97-1.43) for HPV16 E6.
The sensitivity analysis using a threshold of 5.30 lnMFI
also showed no evidence of an association (P > 0.05 for
all) (Additional file 2: Table S2). Additional sensitivity
analyses that included adjustment for education and ever
smoking did not differ substantially from the main ana-
lyses with threshold at 5.99 lnMFI or the alternative
threshold of 5.30 lnMFI (<10 % change in the odds ratio)
(Additional file 3: Table S3 and Additional file 4: Table
S4 respectively).
Exploratory boxplots showed no evidence of an associ-
ation between antigen-specific antibodies and any spe-
cific lung cancer histology (Figs. 1, 2 and 3).
Discussion
In this seroepidemiologic study of the association of
HPyV and HPV and incident lung cancer in Asia, multi-
variable regression analyses of pooled histology types
and visual exploration of boxplots stratified by histology
type demonstrated no evidence of an association be-
tween the levels of these viral antibodies and lung can-
cer. These results are consistent with our previous
seroepidemiologic study in an American population,
which also found no association between HPyV antibody
levels and lung cancer [21].
Only one small European study using nucleic acid
amplification testing (NAAT) to detect viral DNA found
a strong association between lung cancer of undescribed
histology and KIV [15]. Subsequent NAAT based studies
of KIV and small cell carcinoma and large cell neuroen-
docrine carcinoma [16], adenocarcinoma [17], and small
cell neuroendocrine carcinoma [18] all failed to confirm
these positive findings. Among the studies of MCV and
WUV in association with lung cancer, the majority did
Table 2 The distribution of antigen specific antibodiesa among
lung cancer cases and controls
Cases Controls
(n = 183) (n = 217)
Antibody Mean SD Mean SD Difference
HPyV
MCVb VP1c 8.4 2.5 8.4 2.5 0
MCVb ST-Agd 1.1 1.8 1.1 2 0
KIVe VP1 c 9 1.9 8.9 1.5 0.1
KIVe ST-Agd 1.9 1.9 1.9 1.9 0
WUVf VP1 c 9.2 1 9.1 .8 0.1
WUVf ST-Agd 1.7 1.8 1.6 1.7 0.1
HPVg 16
E6 .4 1.2 .2 1 0.2
E7 1.7 2.6 1.4 2.3 0.3
L1 1.3 2.1 1.1 1.9 0.2
HPVg 18
E6 1.6 2 1.5 1.9 0.1
E7 .6 1.6 .5 1.4 0.1
L1 2.1 2 2.1 1.9 0
Other high-risk HPVg
31 L1 2.6 2.3 2.6 2.5 0
33 L1 1.8 2 1.7 1.9 0.1
52 L1 5 2 5 1.9 0
58 L1 3.5 2.4 3.4 2.3 0.1
Low-risk HPVg
6 L1 5.1 2.7 4.9 2.6 0.2
11 L1 4 2.4 3.7 2.4 0.3
a Measured in units of natural log transformed median fluorescence intensity
(lnMFI). The “Mean” is the arithmetic mean, “SD” is the standard deviation, and
“Difference” is equal to the mean of the cases minus the mean of the controls
b MCV =Merkel cell polyomavirus
c VP1 = the primary structural protein of human polyomaviruses
d ST-Ag = the small T-antigen of human polyomaviruses
e KIV = KI polyomavirus
f WUV =WU polyomavirus
g HPV = Human papillomavirus
Table 1 Characteristics of selected lung cancer cases and frequency matched controls: Yunnan, China 1992-1998 (Continued)
Middle lobe lung 19 (10.4) 0 (−)
Lower lobe bronchus or lung 60 (32.8) 0 (−)
Other parts of bronchus or lung 3 (1.6) 0 (−)
Bronchus and lung NOS 10 (5.5) 0 (−)
a Highest educational level started
b Having ever smoked tobacco was defined as having smoked cigarettes, pipes, or water pipes for 6 months or longer, or providing an age for beginning or
quitting smoking, or providing a non-zero measure of tobacco smoked daily
c IQR, interquartile range
d Measured in iaem, index of arsenic exposure months, a time weighted arsenic exposure measurement (mg/m3 x months)
e Measured in wlm, working level month
f Family history of lung cancer was defined as having any immediate family member (parents, siblings, children, or spouse) who received a doctor’s diagnosis of
lung cancer
g Any prior lung disease was defined as a prior diagnosis of asthma or hay fever, tuberculosis, chronic bronchitis, or silicosis.
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not have a true comparison group, which limits the abil-
ity to determine possible associations [11, 13, 14, 16–
18]. One study that assessed tumors along with adjacent
benign tissue reported finding MCV DNA in 5 of 30
cases as compared to 2 of 21 controls [12], which pro-
vides a non-statistically significant OR of 1.9.
In contrast to meta-analyses which reported potential
associations between lung cancer and HPV in East Asia
[27, 28, 37], we found no evidence of an association with
seropositivity to eight different HPV types. To date,
more than 100 HPV / lung cancer association studies
have been conducted [37] and wide ranging differences
in reported associations among East Asian countries
have been noted [26]. Since our sero-assay was less sen-
sitive than NAATs, it remains unclear whether previous
positive associations were due to contamination [38, 39]
Table 3 Association between antigen specific human polyomavirus (HPyV) antibody levels and incident lung cancer, adjusted for
matching variables
Mean Trend Testd
Antibody quartile lnMFIa aOR (95%CIb) Pc OR (95%CIb) Pc
MCVe VP1f 1.00 (0.92–1.09) 0.951
1 5.03 Referent
2 8.50 0.67 (0.38–1.17) 0.163
3 9.74 0.80 (0.49–1.31) 0.372
4 12.57 0.90 (0.37–2.17) 0.810
MCVe ST-Agg 0.97 (0.88–1.08) 0.623
1 0.02 Referent
2 0.05 1.01 (0.58–1.76) 0.985
3 0.25 0.70 (0.40–1.22) 0.209
4 4.12 0.85 (0.48–1.48) 0.553
KIVh VP1g 1.04 (0.92–1.17) 0.532
1 6.92 Referent
2 8.65 1.07 (0.61–1.88) 0.821
3 9.32 1.64 (0.94–2.89) 0.089
4 10.81 1.44 (0.82–2.52) 0.206
KIVh ST-Agg 0.99 (0.90–1.10) 0.878
1 0.02 Referent
2 0.22 1 .00 (0.58–1.75) 0.991
3 3.00 0.72 (0.41–1.27) 0.260
4 4.43 1.13 (0.65–1.98) 0.652
WUVi VP1g 1.20 (0.96–1.51) 0.112
1 8.16 Referent
2 8.86 1.34 (0.77–2.36) 0.305
3 9.34 1.15 (0.65–2.01) 0.643
4 10.13 1.47 (0.84–2.58) 0.182
WUVi ST-Agg 1.02 (0.91–1.14) 0.734
1 0.02 Referent
2 0.07 0.95 (0.55–1.67) 0.871
3 2.40 0.83 (0.47–1.45) 0.522
4 4.04 1.02 (0.58–1.78) 0.951
a lnMFI = natural log transformed median fluorescence intensity
b Nominal (uncorrected) 95 % confidence intervals
c P-values are corrected for multiple comparisons using permutation tests
d The trend tests estimate the odds ratio for a one unit increase in natural log transformed MFI, adjusted for matched variables
e MCV =Merkel cell polyomavirus
f VP1 = the primary structural protein of human polyomaviruses
g ST-Ag = the small T-antigen of human polyomaviruses
h KIV = KI polyomavirus
i WUV =WU polyomavirus
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Table 4 Association between human papillomavirus (HPV) seropositivitya and incident lung cancer, adjusted for matching variables
Antibody Cases (n = 200) Controls (n = 200) Trend Testb
% % OR (95 % CIc) Pd OR (95 % CIc) Pd
HPV 16
E6 0.5 1.4 0.39 (0.04–3.79) 0.462 1.17 (0.97–1.43) 0.097
E7 9.3 7.8 1.22 (0.60–2.47) 0.603 1.06 (0.97–1.15) 0.182
L1 4.4 3.7 1.17 (0.43–3.21) 0.746 1.04 (0.95–1.15) 0.374
HPV 18
E6 1.6 1.4 1.18 (0.23–5.93) 0.877 1.02 (0.93–1.13) 0.632
E7 1.6 1.4 1.18 (0.23–5.93) 0.877 1.06 (0.93–1.21) 0.404
L1 0.5 1.8 0.29 (0.03–2.66) 0.229 1.00 (0.91–1.11) 0.948
Other high-risk HPV
31 L1 6.6 8.8 0.72 (0.34–1.53) 0.402 1.00 (0.92–1.09) 0.988
33 L1 0.5 0.5 1.23 (0.08–20.03) 0.887 1.03 (0.93–1.15) 0.537
52 L1 34.4 33.6 1.04 (0.68–1.57) 0.883 1.00 (0.90–1.11) 0.989
58 L1 13.7 12.0 1.17 (0.65–2.10) 0.611 1.03 (0.94–1.12) 0.543
Low-risk HPV
6 L1 45.4 38.2 1.34 (0.89–2.00) 0.167 1.03 (0.95–1.11) 0.503
11 L1 20.2 13.8 1.58 (0.93–2.68) 0.097 1.05 (0.97–1.14) 0.229
a Seropositivity defined as >400 MFI (median fluorescence intensity)
b The trend tests estimate the odds ratio for a one unit increase in natural log transformed MFI, adjusted for matched variables
c Nominal (uncorrected) 95 % confidence intervals
d P-values are corrected for multiple comparisons using permutation tests
Fig 1 Boxplots of human polyomavirus (HPyV) antigen specific antibody distributions, by lung cancer histology type. *The shaded box represents
the inter-quartile range (IQR), the horizontal line within the box represents the median, the vertical lines extend to 1.5 times the IQR, and dots
represent outliers. **Abbreviations: ln(MFI), natural log median fluorescence intensity; SCC, squamous cell carcinoma; ADC, adenocarcinoma; SCLC,
small cell lung cancer
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Fig 2 Boxplots of human papillomavirus (HPV) 16 and 18 antigen specific antibody distributions, by lung cancer histology type. *The
shaded box represents the inter-quartile range (IQR), the horizontal line within the box represents the median, the vertical lines extend to
1.5 times the IQR, and dots represent outliers. **Abbreviations: ln(MFI), natural log median fluorescence intensity; SCC, squamous cell
carcinoma; ADC, adenocarcinoma; SCLC, small cell lung cancer
Fig 3 Boxplots of high-risk (31, 33, 52 and 58) and low-risk (6 and 11) human papillomavirus (HPV) antigen specific antibody distributions, by lung
cancer histology type. *The shaded box represents the inter-quartile range (IQR), the horizontal line within the box represents the median, the
vertical lines extend to 1.5 times the IQR, and dots represent outliers. **Abbreviations: ln(MFI), natural log median fluorescence intensity; SCC,
squamous cell carcinoma; ADC, adenocarcinoma; SCLC, small cell lung cancer
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or whether negative associations were due to differences
in selected primers [26, 27] and the use of formalin-
fixed paraffin embedded specimens, which may hinder
attempts to amplify longer DNA segments [27, 40].
After completing the study and analyzing the data, we
found that ever smoking status and level of education
were associated with case/control status. Both factors
could have potentially confounded the relationship be-
tween viral infection and lung cancer. While we were
unable perform the analysis anew with matching on
smoking history and education, we were able to assess
confounding by including these factors as adjustment
variables in sensitivity analyses. Since inclusion of these
variables in the models did not substantially change the
interpretation of our results, we reported the analysis ad-
justed for matching variables as our primary findings.
The primary limitation of this study is that all cohort
members were at high risk for lung cancer due to occupa-
tional exposures. In the absence of interactive effects, these
potent risk factors may obscure weaker contributions to
lung cancer risk that might be observed in a broader popu-
lation sample. This was by design, since we originally hy-
pothesized that both HPVs and HPyVs might have an
interactive effect with known carcinogens to contribute to
lung cancer risk [41–43]. In addition, the study was under-
powered for the examination of these associations by histo-
logic type. However, some HPV types have been reported
to be strongly associated with squamous cell carcinoma
[28] and Merkel cell carcinoma is histologically similar to
small cell carcinoma [44], so there may not have been an
ideal distribution of histologic types for this study. The lack
of specificity regarding the location of infection is also a
limitation of our design. However, based on the limited
number of seropositive samples, this is unlikely to have
been important in this analysis. We also acknowledge that
serology is not a gold standard for the evaluation of car-
cinogenic viruses associated with solid cancers [45]. Never-
theless, seroepidemiologic methods allow for ready
selection of appropriate controls and are uniquely posi-
tioned to detect evidence for hit-and-run viral oncogenesis
[46]. Finally, as mentioned above, another limitation is the
potential lack of assay sensitivity compared to NAATs. The
primary strengths of this study are the reduced susceptibil-
ity to contamination compared to NAATs and the temporal
element that would have better informed causal inference if
we did observe an association.
Conclusions
In summary, we found no association between KIV,
WUV, and MCV antibody levels or HPV-16, 18, 31, 33,
52, and 58 seropositivity and incident lung cancer in a
high-risk male Asian cohort. Future studies of infectious
etiologies of lung cancer should look beyond HPyVs and
HPVs as candidate infectious agents.
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